Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 11/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18954971 | 0.92 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL25496214 | 0.92 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL10457794 | 0.92 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL25496217 | 0.92 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL19880310 | 0.92 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL19509409 | 0.92 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL1936920 | 0.92 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL19491657 | 0.88 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL19502411 | 0.88 | KDM4E (0.44) | KDM4EALDH1A1MEN1KMT2ATAS1R3 | |
| SCHEMBL24829643 | 0.86 | ALDH1A1 (0.46) | KDM4EALDH1A1MEN1KMT2ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | KDM4E 3375/4885ALDH1A1 4600/4885MEN1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.